BREAST CANCER

The ASCO’s expert panel released updated recommendations of pembrolizumab in combination with neoadjuvant chemotherapy for patients with stage II or stage III early triple-negative breast cancer

Lajos Pusztai, MD, DPhil, discusses multiple analyses of the phase 3 KEYNOTE-522 clinical trial of pembrolizumab plus chemotherapy administered in the neoadjuvant or adjuvant setting to patients with triple-negative breast cancer versus placebo plus chemotherapy.

Comprehensive discussion on the presence and management of interstitial lung disease in patients being treated for HER2+ metastatic breast cancer.

Neil Vasan, MD, PhD, discusses how the results of the TRAIN-2 trial impacted the treatment of patients with HER2-positive breast cancer.

Patients with hormone receptor–positive, HER2-negative advanced breast cancer who had dose modifications of ribociclib had comparable overall survival outcomes to those given the standard dose.

Results of the phase 1 ELAINEI trial will inform the activity of single-agent lasofoxifene in estrogen receptor-positive, HER2-negative metastatic breast cancer with ESR1 mutations.

During a live virtual event, Rita Nanda, MD, discussed with participants how to address toxicities of sacituzumab govitecan and how to treat a patient who progresses after receiving this agent.

Shared insight on the DESTINY-Breast03 trial, which analyzed trastuzumab deruxtecan therapy in patients with HER2+ metastatic breast cancer.

Panelists provide a broad overview of treatment options available for patients diagnosed with HER2+ metastatic breast cancer.

According to Timothy J. Whelan, MD, FASCO, radiotherapy is an inconvenient treatment. It can last daily for up to 5 weeks and it is a costly therapy. Study results shows that is can safely be omitted in the treatment of some patients with luminal A breast cancers.

Several key risk factors seen in the monarchE trial of adjuvant abemaciclib could help early monitoring of patients with hormone receptor–positive, HER2-negative, node-positive high-risk early breast cancer to prevent discontinuation.

Combination of alpelisib and fulvestrant shows clinical benefit in patients with hormone receptor–positive, HER2-negative advanced breast cancer regardless of gene mutation status, according to a retrospective biomarker analysis.

Treatment with ribociclib and an alternate endocrine therapy after progression on a prior CDK4/6 inhibitor improved progression-free survival over placebo and endocrine therapy in patients with HR-positive, HER2-negative unresectable or metastatic breast cancer, according to results of the randomized phase 2 MAINTAIN trial.

According to Ian E. Krop, MD, PhD, patritumab deruxtecan is responsible for producing clinically meaningful and durable antitumor activity in patients with HER3-expressing metastatic breast cancer, warranting further research.

First-line treatment with palbociclib plus letrozole demonstrated survival improvement vs letrozole monotherapy in patients with ER-positive/HER2-negative advanced breast cancer.

A safety follow-up analysis of the randomized phase 3 DESTINY-Breast03 study reinforced the risk-benefit profile of trastuzumab deruxtecan compared with trastuzumab emtansine in patients with HER2-positive unresectable or metastatic breast cancer

A 34% reduction in the risk of disease progression was observed with sacituzumab govitecan vs standard chemotherapy as treatment of patients with hormone-receptor-positive and HER2-negative metastatic breast cancer.

Physicians cover the options for a patient with hormone receptor–positive, HER2-negative, early-stage breast cancer, which course of action they would take, and the data supporting that choice.

During a Targeted Oncology case-based roundtable event, Stephanie L. Graff, MD, discussed the case of a patient with triple-negative breast cancer who progressed following adjuvant chemotherapy and frontline carboplatin treatment.

A focused discussion on the subcutaneous formulation of trastuzumab and pertuzumab in patients with early-stage HER2+ breast cancer.

Shifting their focus to the adjuvant setting, expert panelists review the optimal selection of therapy following surgery in early-stage HER2+ breast cancer.

Charles Geyer, MD, discusses the end point that was met within the OlympiA study.

During a case-based roundtable event, Foluso Olabisi Ademuyiwa, MD, MPH, MSCI and a group of peers discussed the benefits and challenges with using sacituzumab govitevan to treat a 48-year-old patients with triple-negative breast cancer.

According to a survey, some Black patients with metastatic breast cancer harbor distrust toward clinical trials, which has impacted the number of Black patients who participate.

Charles E. Geyer, MD, discusses the efficacy of olaparib in the OlympiA study of patients with BRCA-positive, HER2-negative high-risk early breast cancer.

Comprehensive insight on the neoadjuvant treatment armamentarium for early-stage HER2+ breast cancer and the appropriate selection of specific agents.

Centering discussion on a patient case of early-stage HER2+ breast cancer, expert oncologists consider when it is appropriate to utilize neoadjuvant therapy.

A phase 1b trial of ALRN-6924 in patients with p53-mutated breast cancer who are being treated with doxorubicin plus cyclophosphamide and docetaxel has treated its first patients.

A new trial will investigate the combination of ZEN-3694 and talazoparib in patients who previous received a TROP2 antibody-drug conjugate.

During a live virtual event, Rita Nanda, MD, discussed the choice of therapy for a patient whose metastatic triple-negative breast cancer recurred after adjuvant chemotherapy with paclitaxel.